T1	PrimaryOutcome 50 78	time to clinical improvement
T2	OutcomeDefinition 95 226	time from randomization (D0) to an improvement of 2 points on a 7-category ordinal scale or live discharge from the hospital (Dend)
T3	PrimaryOutcome 232 270	improvement rate of follow-up CT scans
T4	TimeFrame 271 277	at D14
R1	MeasuredAt Arg1:T3 Arg2:T4	
T5	OtherOutcome 550 575	clinical improvement rate
T6	TimeFrame 622 646	on D7, D14, D21, and D28
R2	MeasuredAt Arg1:T5 Arg2:T6	
T7	OutcomeDefinition 576 621	as assessed with the 7-category ordinal scale
R3	DefinedAs Arg1:T5 Arg2:T7	
T8	OtherOutcome 648 733	time from randomization to lymphocyte recovery and to invasive mechanical ventilation
T9	OtherOutcome 739 779	duration of hospitalization in survivors
T10	OtherOutcome 789 828	time from treatment initiation to death
T11	OtherOutcome 892 927	incidence of serious adverse events
T12	TimeFrame 938 951	up to 28 days
R4	MeasuredAt Arg1:T11 Arg2:T12	
T13	OtherOutcome 978 992	adverse events
T14	OtherOutcome 997 1019	serious adverse events
T15	OtherOutcome 1088 1217	impact of ruxolitinib on SARS-CoV-2 virus clearance and its specific IgM and/or IgG-antibody formation and/or lymphocyte recovery
T16	OutcomeDefinition 1381 1475	the first day at which lymphocytes returned to the normal levels within the observation period
R5	DefinedAs Arg1:T8 Arg2:T16	
T17	OutcomeDefinition 1521 1638	time from randomization to the first day of at least 2 consecutive negative RT-PCR assays separated by 24 hours apart
T18	OtherOutcome 833 853	virus clearance time
R6	DefinedAs Arg1:T18 Arg2:T17	
T19	SecondaryOutcome 1671 1688	overall mortality
T20	OtherOutcome 1739 1774	dynamic changes in the virus copies
T21	OtherOutcome 1776 1792	cytokine profile
T22	OtherOutcome 1794 1823	SARS-CoV-2â€“speicific antibody
T23	OtherOutcome 1833 1877	correlation with clinical treatment response
T24	TimeFrame 1689 1695	at D28
R7	MeasuredAt Arg1:T19 Arg2:T24	
